Riverwater Partners, an investment management company, released its “Micro Opportunities Strategy” Q2 2026 investor letter. A copy of the letter is available to download here. In Q2 2026, the Micro Opportunities strategy underperformed the Russell Microcap Index, despite a positive absolute result. The benchmark performed well during a speculative period for micro caps. Over the past twelve months, the strategy has lagged behind the index. Industrials was the best-performing sector while Information Technology lagged. An accelerating artificial intelligence buildout and a persistent geopolitical supply shock drove the market in the quarter. While the micro-cap rally exhibited speculative traits with significant returns in areas avoided by design. The Fund’s focus remains on owning profitable, well-managed small businesses at reasonable prices rather than pursuing fleeting market trends. In addition, please check the Strategy’s top five holdings to know its best picks in 2026.
In its Q2 2026 investor letter, Riverwater Micro Opportunities Strategy highlighted Iradimed Corporation (NASDAQ:IRMD). Iradimed Corporation (NASDAQ:IRMD) is a medical device company focusing on developing MRI-compatible intravenous infusion pump systems and patient monitoring systems. On July 24, 2026, Iradimed Corporation (NASDAQ:IRMD) closed at $94.49 per share, reflecting a market capitalization of $1.21 billion. Iradimed Corporation (NASDAQ:IRMD) posted a one-month return of 0.45%, while its shares gained 65.45% over the past 52 weeks.
Riverwater Micro Opportunities Strategy stated the following regarding Iradimed Corporation (NASDAQ:IRMD) in its Q2 2026 investor update:
“Several sales reflected valuation and sizing discipline. We trimmed Iradimed Corporation (NASDAQ:IRMD) in early May: the position had grown beyond 5% of the portfolio, near-term earnings comparisons are demanding, and the valuation was extended, though the fundamental story remains intact as the company’s new IV pump configurations carry list prices more than double the prior generation.”
Iradimed Corporation (NASDAQ:IRMD) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 20 hedge fund portfolios held Iradimed Corporation (NASDAQ:IRMD) at the end of the first quarter, up from 19 in the previous quarter. While we acknowledge the risk and potential of Iradimed Corporation(NASDAQ:IRMD) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than Iradimed Corporation (NASDAQ:IRMD) and that has 10,000% upside potential, check out our report about this cheapest AI stock.
In another article, we covered Iradimed Corporation (NASDAQ:IRMD) and shared the list of best micro and small cap stocks to buy according to Jim Simons’ Renaissance Technologies. In addition, please check out our hedge fund investor letters Q2 2026 page for more investor letters from hedge funds and other leading investors.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. This article is originally published at Insider Monkey.
